Home/Filings/4/0001127602-14-033303
4//SEC Filing

LIPOSCIENCE INC 4

Accession 0001127602-14-033303

CIK 0001168197operating

Filed

Nov 23, 7:00 PM ET

Accepted

Nov 24, 3:15 PM ET

Size

19.0 KB

Accession

0001127602-14-033303

Insider Transaction Report

Form 4
Period: 2014-11-20
Otvos James D.
EVP, Chief Scientific Officer
Transactions
  • Disposition to Issuer

    Common Stock

    2014-11-20$5.25/sh180,167$945,8770 total(indirect: By Spouse)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-11-20$1.37/sh16,160$22,1390 total
    Exercise: $3.88Exp: 2017-02-15Common Stock (16,160 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-11-20$2.79/sh52,380$146,1400 total
    Exercise: $2.46Exp: 2017-10-25Common Stock (52,380 underlying)
  • Disposition to Issuer

    Common Stock

    2014-11-20$5.25/sh504,771$2,650,0480 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-11-20$2.75/sh2,000$5,5000 total
    Exercise: $2.50Exp: 2015-05-05Common Stock (2,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-11-20$2.79/sh6,308$17,5990 total
    Exercise: $2.46Exp: 2018-04-29Common Stock (6,308 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-11-20$2.75/sh19,254$52,9490 total
    Exercise: $2.50Exp: 2019-02-06Common Stock (19,254 underlying)
Footnotes (12)
  • [F1]Disposed of pursuant to the Merger Agreement and includes 23,151 shares of the Issuer's common stock underlying restricted stock unit awards.
  • [F10]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $17,639.69, which represents the difference between the merger consideration of $5.25 per share and the exercise price of the option per share.
  • [F11]The option was fully vested upon issuance on February 6, 2009.
  • [F12]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $53,048.62, which represents the difference between the merger consideration of $5.25 per share and the exercise price of the option per share.
  • [F2]Disposed of pursuant to the Merger Agreement.
  • [F3]The option was fully vested upon issuance on May 5, 2005.
  • [F4]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $5,510.40, which represents the difference between the merger consideration of $5.25 per share and the exercise price of the option per share.
  • [F5]The option was fully vested upon issuance on February 15, 2007.
  • [F6]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $22,198.99, which represents the difference between the merger consideration of $5.25 per share and the exercise price of the option per share.
  • [F7]The option was fully vested upon issuance on October 25, 2007.
  • [F8]Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $146,475.44, which represents the difference between the merger consideration of $5.25 per share and the exercise price of the option per share.
  • [F9]The option was fully vested upon issuance on April 29, 2008.

Issuer

LIPOSCIENCE INC

CIK 0001168197

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001168197

Filing Metadata

Form type
4
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 3:15 PM ET
Size
19.0 KB